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Prion diseases (transmissible spongiform encephalopathies) are fatal neurodegenerative diseases, including
Creutzfeldt-Jakob disease in humans, scrapie in sheep and bovine spongiform encephalopathy in cattle.
While genome-wide association studies in human and quantitative trait loci mapping in mice have provided evi-
dence for multiple susceptibility genes, few of these have been confirmed functionally. Phenotyping mouse
models isgenerally the method of choice. However, this is nota feasible option where many novel genes, without
pre-existing models, would need to be tested. We have therefore developed and applied an in-vitro screen to
triage and prioritize candidate modifier genes for more detailed future studies which is faster, far more cost
effective and ethical relative to mouse bioassay models. An in vitro prion bioassay, the scrapie cell assay,
uses a neuroblastoma-derived cell line (PK1) that is susceptible to RML prions and able to propagate prions
at high levels. In this study, we have generated stable gene silencing and/or overexpressing PK1-derived cell
lines to test whether perturbation of 14 candidate genes affects prion susceptibility. While no consistent differ-
ences were determined for seven genes, highly significant changes were detected for Zbtb38, Sorcs1, Stmn2,
Hspa13,Fkbp9,Actr10andPlg,suggesting that they play key roles in the fundamental processes of prion propa-
gation or clearance. Many neurodegenerative diseases involve the accumulation of misfolded protein aggre-
gates and ‘prion-like’ seeding and spread has been implicated in their pathogenesis. It is therefore expected
that some of these prion-modifier genes may be of wider relevance in neurodegeneration.
INTRODUCTION
Prion diseases (transmissible spongiform encephalopathies) are
fatal neurodegenerative diseases including variant and sporadic
Creutzfeldt-Jakob disease (CJD) in human, scrapie in sheep and
bovine spongiformencephalopathy in cattle. They are character-
ized by a long, clinically silent, incubation period and patho-
logically exhibit neuronal loss, spongiform vacuolation of the
neuropil and the accumulation of abnormal forms of the prion
protein (often designated PrPSc) in the brain.
Human prion diseases may be sporadic, inherited or acquired,
yet genetic susceptibility plays an important role regardless of
aetiology. The major genetic component is the prion protein
gene (PRNP) itself particularly a polymorphism at codon 129
whereby thepresenceofeithermethionineorvaline, andzygosity,
has a profound influence on susceptibility, age of onset and dur-
ation of disease (1–3). Despite the primacy of PRNP, several
studies have now confirmed that many other genes contribute
to overall genetic susceptibility. Genome-wide association
studies (GWAS) carried out indifferent humanpriondiseases in-
cluding variant CJD (vCJD), iatrogenic CJD, sporadic CJD
(sCJD) and kuru identified multiple loci of potential interest
(4–6).
Identification of human susceptibility genes in rare diseases is
challenging; therefore, parallel studies havealsobeencarriedout
in mice using incubation time as a phenotype. Mouse models in
prion disease are particularly useful as unlikemany other neuro-
degenerative diseases; mice are naturally susceptible to prions
and faithfullymirror the clinical and pathological characteristics
of the human disease, including the major genetic influence of
Prnp. Quantitative trait loci (QTL) mapping studies confirmed
the influence of genes other thanPrnp in determining incubation
time and additional fine mapping and differential expression
studies have suggested numerous candidate genes (7–11).
∗To whom correspondence should be addressed.Tel: +44 2076762187; Fax: +44 2076762180; Email: s.lloyd@prion.ucl.ac.uk
# The Author 2014. Published by Oxford University Press.
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/ .0/),
which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.
Human Molecular Genetics, 2014, Vol. 23, No. 19 5102–5108
doi:10.1093/hmg/ddu233
Advance Access published on May 15, 2014
4
 at U
CL Library Services on Septem
ber 23, 2014
http://hm
g.oxfordjournals.org/
D
ow
nloaded from
 
Prion disease susceptibility genes have been described in
many studies in both human and mouse and with varying
degrees of statistical confidence; the main challenge is now to
verify their role in a functional assay that is relevant to the
disease. The standard experimental paradigm is to knockout or
overexpress the gene of interest in a mouse model, inoculate
withprionsandcompareall aspectsof thephenotype, particularly
incubation time, with wild-type controls. Mouse bioassay is
costly and time consuming particularly if appropriate mouse
models do not already exist. Furthermore, many of these genes
are novel with little or no information available in the literature
andhavenopreviouslyknown links topriondisease orotherneu-
rodegenerative processes. It is not always clear which genes are
likely to be the most informative and it is not feasible to actively
pursue all these candidates in vivo by making new animal
models.Wheremultiple candidate genes require testing, the con-
straints ofmouse bioassays become prohibitive necessitating the
development of a fast, reliable, ethical and cost-effective in-vitro
screen to provide a measure of prion-related function to assist
with prioritization for in-depth functional genomics.
Here, we describe an in-vitro screening assay that combines
the scrapie cell assay (SCA) in prion susceptible neuroblastoma-
derived cells (PK1) with silencing or overexpression of candi-
date genes (12). PK1 cells are a subline of N2a cells highly
selected for their susceptibility to infection with the Chandler/
RML prion strain and ability to propagate prions at high levels
indefinitely. In the standard SCA, RML prions are applied to
PK1 cells, the cells become infected and prions are propagated.
During this time, cells continue to divide and prions accumulate.
Cells are passaged into fresh medium every 3 days at least three
times to ensure sufficient dilution that the original inoculum is
no longer present. Infectivity is quantified by calculating the
number of infected cells using an enzyme-linked immunospot
(ELISPOT) assay based on the immunodetection of PrPSc.
Proof of principle has already been established that knockdown
of Prnp in PK1 cells results in the inhibition of prion propaga-
tion, suggesting that the application of the SCA combined with
manipulation of gene expression may be an effective screening
tool (13). In this study, we have generated stable cell lines
rather than relying on transient expression of constructs so that
knockdown or overexpression is effective throughout the dur-
ation of the assay. This allows the detection of gene effects
that modify early events such as infectivity uptake and propaga-
tion as well as longer term effects such as PrPSc accumulation,
clearance and cell-to-cell spread.
RESULTS
Candidate genes were selected for functional screening from a
variety of sources including human GWAS, mouse differential
expression, QTL and association studies (4,11,14–20) (Tables 1
and 2). In the first instance, the aim was to generate at least two
stable knockdown cell lines per gene with mRNA expression
reduced at least 50% relative to control cells. This was to ensure
reproducible results and to minimize the possibility of spurious
results due to off-target effects. Green fluorescent protein-
knockdowncell linesweregenerated inparallel as a non-targeting
control to ensure that anyobserved differenceswere not due to the
vector and antibiotic selection. For each gene, at least four shRNA
sequences were designed and cloned into the pRetroSuper (Oli-
goengine) retroviral vector (Supplementary Material, Table S1).
Following production of virus, mouse neuroblastoma-derived
N2aPK1/2cells (12)were transducedandgrownunderpuromycin
selection toderive stablecell lines.The level ofmRNAexpression
relative to control cells was determined by real-time RT-PCR.
Eleven candidate genes were successfully targeted comprising
39 cell lines with a mean mRNA knockdown of 71% (37–98%)
relative to the control cell line (Table 1).
For Rarb,Cpne8 and Plg, the level of endogenous mRNA ex-
pression in N2aPK1/2 cells was either very low or undetectable
by real-time RT-PCR rendering them unsuitable for a knock-
down approach. cDNA sequences comprising the open reading
frames were cloned into the pLNCX2 retroviral vector (Clon-
tech) to generate overexpressing N2aPK1/2 stable cell lines
under neomycin selection as above (Supplementary Material,
Table 1. Knockdown cell lines
Gene Source (M/H) Cell line % KD
mRNA
SCA fold
difference
P-value
Zbtb38 GWAS (H) Zbtb38sh1 60 0.24 ,0.0001
Zbtb38sh2 42 0.48 ,0.0001
Sorcs1 GWAS (H) Sorcs1sh1 43 0.44 ,0.0001
Sorcs1sh5 37 0.41 ,0.0001
Sorcs1sh6 47 0.27 ,0.0001
Sorcs1sh7 64 0.40 ,0.0001
Sorcs1sh8 54 0.71 ,0.0001
Rchy1 GWAS (H) Rchy1sh2 95 – ns
Rchy1sh3 88 – ns
Stmn2 GWAS (H) and SNP
association (M)
Stmn2sh1 80 0.23 ,0.0001
Stmn2sh4 80 0.21 ,0.0001
Hspa13 Microarray (M) Hspa13sh1 70 0.45 ,0.0001
Hspa13sh4 65 – ns
Hspa13sh5 63 0.77 0.0007
Hspa13sh6 53 – ns
Hspa13sh7 82 0.52 ,0.0001
Hspa13sh8 85 0.40 ,0.0001
Fkbp9 Microarray (M) Fkbp9sh2 96 20.67 ,0.0001
Fkbp9sh3 91 10.23 ,0.0001
Fkbp9sh4 92 9.44 ,0.0001
Actr10 Microarray (M) Actr10sh1 61 13.71 ,0.0001
Actr10sh2 84 6.39 ,0.0001
Actr10sh3 66 5.01 ,0.0001
Actr10sh4 71 4.33 ,0.0001
Cbx1 Microarray (M) Cbx1sh1 65 – ns
Cbx1sh2 65 – ns
Cbx1sh3 66 – ns
Cbx1sh4 76 – ns
Gpr19 Microarray (M) Gpr19sh1 92 1.63 ,0.0001
Gpr19sh5 80 0.56 ,0.0001
Gpr19sh6 66 – ns
Gpr19sh7 54 – ns
Gpr19sh8 61 1.43 0.0007
Hectd2 QTL (M) and SNP
association (H)
Hectd2sh1 96 2.14 ,0.0001
Hectd2sh3 96 – ns
Hectd2sh4 98 1.91 ,0.0001
Sod1 SNP association (M)
and transmission
studies
Sod1sh1 67 0.33 ,0.0001
Sod1sh3 77 – ns
Sod1sh4 62 – ns
Bonferonni-corrected significance at 1% is taken as P,0.001.
GWAS, genome-wide association study; SNP, single nucleotide polymorphism;
QTL, quantitative trait locus;M,mouse;H, human; SCA, scrapie cell assay. SCA
mean fold difference and P-value are calculated from three independent
experiments. SCA fold difference values below 1 indicate a reduction and above
1 an increase in spot number. ns, not significant.
Human Molecular Genetics, 2014, Vol. 23, No. 19 5103
 at U
CL Library Services on Septem
ber 23, 2014
http://hm
g.oxfordjournals.org/
D
ow
nloaded from
 
Table S2). Similarly, overexpressing lines were also generated
for an additional seven genes to complement the knockdown
lines (Table 2). Control cell lines were generated in parallel
using the pLNCX2 empty vector. Overexpression was con-
firmed by real-time RT-PCR. Similar levels of mRNA expres-
sion were obtained for all cell lines as directed by the CMV
promoter (Table 2).
Each cell line was tested in three independent SCAs with the
mouse adapted scrapie prion strain Chandler/RML. The com-
bined results for three independent experiments are shown in
Tables 1 and 2 (Supplementary Material, Fig. S1).
STMN2 was identified as a prion disease susceptibility factor
in vCJD, and ZBTB38 and SORCS1 were identified in a
meta-analysis of vCJD, sCJD and kuru resistance GWAS data
(4,14). Highly significant reductions (P , 0.0001) in PrPSc
spot number were seen in knockdown cell lines for Zbtb38
(n ¼ 2; x0.24 and x0.48), Sorcs1 (n ¼ 5; x0.44, x0.41, x0.27,
x0.40, x0.71) and Stmn2 (n ¼ 2; x0.23, x0.21) (Table 1).
Hspa13, Fkbp9 and Actr10were identified in a mouse differ-
ential expression study that selected genes based on the correl-
ation between mRNA expression level and incubation time
across a range of inbred mice (11). siRNA knockdown of
Hspa13 in chronically infected cells previously resulted in clear-
ance from the cells with 40% reduction in PrPSc positive cells
relative to non-targeting control. In this study, six stable knock-
down cell lines were generated forHspa13 to measure the effect
ofknockdownonearly events suchas susceptibility, propagation
and cell-to-cell spread rather than just clearance. Four of the six
cell lines showed a significant reduction in the number of
infected cells relative to the control (0.45-, 0.77-, 0.52- and
0.40-fold difference, Table 1). These data support the previous
in-vitro clearance data and are consistentwith thedifferential ex-
pression data that a decrease in mRNA expression is associated
with a longer incubation time (11). An overexpressing cell line
was also made forHspa13; however, this did not show any con-
verse increase in spot number.
Three knockdown cell lines for Fkbp9 were generated with
.90% mRNA knockdown and all three showed an increase in
the number of PrPSc positive cells (10–21-fold difference,
P, 0.0001, Table 1). The Fkbp9 overexpressing line mirrored
these data showing a decrease in PrPSc spot number (0.74-fold
difference, P, 0.0001, Table 2). Similarly, four knockdown
cell lines for Actr10 showed an increase in spot number
(4–14-fold difference, P , 0.0001, Table 1) and this was sup-
ported by reduced susceptibility in the Actr10 overexpressing
line (0.66-fold difference, P , 0.0001). These data are consist-
ent with the original observation that for both Fkbp9 and
Actr10, a lower mRNA expression level correlates with a
shorter incubation time (11).
Plasminogen (Plg) has been shown to interact with PrP and on
addition to both in-vitro amplification systems (PMCA—protein
misfolding cyclic amplification) and prion-infected N2a cells,
hasbeen shown to increasePrPSc levels (20,21). In contrast, chal-
lenge of plasminogen-deficient mice (Plg2/2) intraperitoneally
withRMLscrapie prions showednomajor effect of plasminogen
on survival, although levels of PrPSc were higher in wild-type
mice at the onset of disease symptoms (22). To address the
role of plasminogen in prion propagation, we generated a
stably overexpressing N2aPK1/2 cell line for inclusion in our
screening assay. A 2.7-fold increase in spot number was
observed (P, 0.0001) thus supporting the previous in vitro
findings (20).
Hectd2was first identified in mouse mapping studies and con-
firmed as a candidate in human prion disease association studies
(15). Three knockdown cell lines, each with mRNA knockdown
.95%, were generated. Two of the three lines (Hectd2shRNA1
and 4) showed a significant increase in the number of infected
cells (2.14- and 1.91-fold difference, respectively, P, 0.0001).
Hectd2shRNA3 showed no difference in spot number and it is
possible that this may be related to siRNA off-target effects.
The Hectd2 overexpressing line also showed a similar increase
in spot number (1.93-folddifference,P, 0.0001)which is incon-
sistent with the data from the knockdown cell lines.
Data for Gpr19 and Sod1 knockdowns were inconclusive as
significant findings were seen in opposite directions for Gpr19
and the decrease in spot number for Sod1 knockdown was seen
in only one of three cell lines. These data were not resolved by
overexpression as no significant differences were seen for
either gene.
No significant differences in spot number were observed
either by knockdown or overexpression for Rchy1, Cbx1, Rarb
or Cpne8 despite achieving high levels of knockdown in at
least two cell lines (Rchy1.88% andCbx1.65%) and consist-
ent levels of overexpression.
The growth rate and differentiation status of N2aPK1/2 cells
are factors that may affect the final number of PrPSc positive
cells at the end of the assay. The SCA output is controlled by
plating a defined number of cells per well (25 000) onto the
ELISPOT plate for final counting; however, growth rates for in-
dividual cell lineswere also estimated (SupplementaryMaterial,
Fig. S2).Nodifferences in doubling timeswere seen in anyof the
cell lines tested, suggesting that the differences in PrPSc spot
number observed for Zbtb38, Sorcs1, Stmn2, Hspa13, Fkbp9,
Actr10 and Plg are not artefacts related to growth rate.
Table 2. Overexpressing cell lines
Gene Source (M/H) Fold
increase
mRNA
SCA fold
difference
P-value
Rarb GWAS (H) and SNP
association (M)
nd – ns
Hspa13 Microarray (M) 140 – ns
Fkbp9 Microarray (M) 9 0.74 ,0.0001
Actr10 Microarray (M) 4 0.66 ,0.0001
Cbx1 Microarray (M) 2 – ns
Gpr19 Microarray (M) 5 – ns
Hectd2 QTL (M) and SNP
association (H)
13 1.93 ,0.0001
Cpne8 QTL (M) nd – ns
Sod1 SNP association (M) and
transmission studies
3 – ns
Plg PrP binding nd 2.70 ,0.0001
SCA mean fold difference and P-value are calculated from three independent
experiments. SCA fold difference values below 1 indicate a reduction and above
1 an increase in spot number. Bonferonni-corrected significance at 1% is taken as
P , 0.001. The level of mRNA expressionwas similar for all lines reflecting the
common CMV promoter. Fold increase in the mRNA expression level was not
calculated (nd) where the endogenous levels were very low or undetectable.
GWAS, genome-wide association study; SNP, single nucleotide polymorphism;
QTL, quantitative trait locus; M, mouse; H, human; SCA, scrapie cell assay.
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PrPexpression is central to prion susceptibility and incubation
time asdemonstrated inmousemodels and in-vitro,wherebyPrP
expression is necessary for prion replication and overexpression
of PrP in transgenicmice results in a decrease in incubation time
(13,23–25). PrP knockdown in PK1 cells significantly reduces
susceptibility and cures chronically infected cells. However,
cell susceptibility is not increased by increasing the level of
PrP expression (11,13,26). Furthermore, comparison of N2a
cell clones during selection of N2aPK1 revealed no differences
in PrP expression in highly susceptible and resistant clones (12).
Based on these precedents, we would not expect the increase in
prion-infected cells in some of our lines to be related to an
increase in PrPC expression. Nevertheless, it is possible that a
decrease in PrPC expression could explain the decrease in spot
number. We therefore measured PrPC expression levels by
enzyme-linked immunosorbent assay (ELISA) in all cell lines.
No differences in PrPC levels were detected in any of our cell
lines (Supplementary Material, Fig. S3).
DISCUSSION
In prion diseases andother conditions includingneurodegenera-
tive diseases such as Alzheimer’s, genetic modifiers are of
considerable interest as a means of identifying risk factors
but also to identify rate limiting steps that may provide useful
therapeutic targets. For prion diseases, the classical method for
evaluating candidate genes is to generate mouse models such
as transgenic or knockout animals and to measure aspects of
phenotype particularly incubation time following prion inocu-
lation. This will continue to be the method of choice for more
detailed pathogenetic studies. However, current genome-wide
studies are now generating large numbers of candidate modifier
genes that cannot bedifferentiated further bygenetic studies and
a higher throughput, more cost-effective and ethical in-vitro
screen is required to prioritize candidates for in-depth in vivo
analysis.
The aimof this studywas therefore to generate stable cell lines
either knocked-down or overexpressing potential modifiers for
testing in the SCA as a first round triage to validate candidates
and prioritize genes for further studies (12). The candidate
gene list for this study was compiled from a diverse range of
studies, including linkage to prion disease incubation time in
mice,microarray expression and an associationwith susceptibil-
ity to human prion disease. These are complex phenotypes that
are likely tobe the result ofmultiple genes, pathways and cellular
mechanisms and may also reflect prion strain and route of
infection-specific events. It is therefore probable that some
genes, which may have a genuine role in prion disease, will
not produce a detectable effect in this in vitro assay. Only posi-
tive results in the SCA are informative, while negatives cannot
be interpreted. However, the main objective was to identify
modifiers that influence the central processes and key compo-
nents of prion propagation and cellular clearance, and these
are expected to be present in N2aPK1/2 cells as well as expres-
sing the PrP ligands and crucial co-factors required for infectiv-
ity and propagation. The cells provide a good model of
infectivity uptake, prion propagation, cell-to-cell spread and
clearance, although unlike neurons in an in-vivo infection they
are able to tolerate prion infectionwithout undergoing cell death.
A potential limitation of this assay is that it only reports with
RML prions and may not identify strain-specific modifiers. It is
therefore possible that strain-specific genesmaynot report in this
assay. This was not considered to be a problem here, as our
objective was to identify genes of general importance within
the central pathways of prion activity rather than strain-specific
modifiers and our aim was to triage genes to prioritize future
work thereby accepting that some genuine modifiers may be
overlooked. For genes progressed to in vivo studies, confirm-
ation of strain-independent effects may be established by
bioassay.
In this study, we have tested 14 candidate modifier genes and
obtained positive SCA results for seven genes. Given that it is
currently unknown whether these candidates are genuine modi-
fiers of prion disease, we are unable to determine the sensitivity,
specificity and predictive value of the SCA. False negativesmay
occur formany reasons including strain-specific factors or inter-
action with pathways that may not be active in N2aPK1 cells.
Similarly, positive results in the SCA may not be replicated in
mice due to the inherent differences between a cell and animal
model. Alternatively, results may prove to be RML-specific
and may not be replicated with other prion strains.
Additional factors that may influence the read out from the
SCA are cell viability, differentiation state, growth rate of cells
and effects on PrP expression levels. No differences in either
growth or PrP expression were observed and experiments were
controlled to account for cell numbers and expressed as normal-
ized values to allow for inter-experiment variation.
The identification of susceptibility genes for rare diseases is
particularly challenging given the limited number of patients
available for study and the threshold for statistical significance
in GWAS is very high. In spite of these demands, several
human candidate genes have been proposed (4,14). However,
themodest effects observed in genetic studies require particular-
ly effective functional tests to differentiate the most promising
genes. Five genes derived from human GWAS were tested in
our in-vitro assay (ZBTB38, SORCS1, STMN2, RCHY1 and
RARB), three of which (ZBTB38, SORCS1 and STMN2)
showed a highly significant reduction in susceptibility in
knocked-down cell lines, providing the first functional evidence
of a role in prion disease. This suggests a role in a fundamental
aspect of prion disease as these genes were initially identified
with human prion strains in case–control studies which may
be measuring a range of susceptibility factors including for
example uptake of prions from the environment or periphery
which are not measurable in this assay. It is possible that the
human genes that do not report in this assay have prion strain-
specific roles or require allele specific modifications in cells to
alter the phenotype. It is also worth noting that the N2aPK1/2
cells are already highly susceptible to prion infection having
undergone several rounds of selection. Therefore, as seen with
Prnp overexpression, it may not always be possible to further in-
crease susceptibility by manipulating certain pathways (12,26).
In these cases, negative results are inconclusive.
ZBTB38 (also known as CIBZ) is a zinc finger transcriptional
regulator that binds methylated DNA. It has also been identified
as a caspase 3 substrate and down regulation ofZbtb38 in C2C12
cells induces apoptosis (27). RML-infected N2aPK1/2 and
stably knocked-down Zbtb38 cells do not undergo apoptosis,
suggesting that an alternative pathway may be affected.
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SORCS1 encodes a member of the vacuolar protein sorting
family involved in endosomal trafficking and the intracellular
sorting of proteins for delivery to the correct cellular location.
SORCS1 has been previously implicated in neurodegeneration
by genetic association with Alzheimer’s disease as well as
with APP processing whereby reduced expression of SORCS1
is associated with increased g-secretase processing and Ab
levels possibly as a result of altered trafficking (28). Total
PrPC is not affected by Sorcs1 knockdown in N2aPK1/2 cells;
however, it is possible that altered PrP trafficking may reduce
its conversion to PrPSc or facilitate its clearance from the cell.
STMN2 encodes the protein SCGN-10 (neuronal growth asso-
ciated protein) and is implicated in neurodegeneration through
its function related to regulating microtubule stability which is
thought to mediate neuronal growth and plasticity (29). While
the growth rate of Stmn2 knockdown N2aPK1/2 does not
appear different from control cells, altered microtubule stability
may affect cellular trafficking of PrPC and PrPSc.
Hspa13, Fkbp9, Actr10, Cbx1 andGpr19were identified in a
mouse differential expression study and three of these (Hspa13,
Fkbp9 and Actr10) showed significant differences in PrPSc spot
numbers in the SCA. Hspa13 is a Ca2+ induced member of the
Hsp70 ATPase protein chaperone family. A significant reduc-
tion in infected cells was seen in four of sixHspa13 knockdown
cell lines, supporting the previously described curing of chronic-
ally infected cells by siRNA knockdown and transgenic mouse
data showing a decrease in incubation time (11). Cell lines
Hspa13sh4 and Hspa13sh6 did not show a reduction in spot
number which may reflect the less efficient mRNA knockdown
in these lines. Hspa13sh5 shows a significant reduction in spot
number even though the level of mRNA knockdown is similar
to that of Hspa13sh4. However, the number of infected cells is
20%higher than forHspa13sh1, 7 and 8.No corresponding in-
crease in spot number was seen in the Hspa13 overexpressing
cell line. Similarly, knockdownofPrnpabolishesprionpropaga-
tion in theSCA,but overexpressiondoes not increase thenumber
of PrPSc positive cells, thus suggesting that Hspa13may interact
with the same pathway (26).
For bothFkbp9 andActr10 knockdown cell lines, a significant
increase in spot numberwas observed and the converse was seen
in their respective overexpressing cell lines.Given thatN2aPK1/
2 cells are already highly susceptible to RML prions and that in-
creasing Prnp expression does not increase cell susceptibility, it
was anticipated that not all potential increases in susceptibility
would be detectable in the SCA. It is therefore likely that
Fkbp9 and Actr10 are increasing susceptibility through an alter-
native pathway. Fkbp9 is a peptidyl–prolyl isomerase and
members of this protein family have been implicated in neurode-
generation, including through accelerating fibrillization
(30–32). No change in PrPC levels are seen in Fkbp9 cells;
however, it is possible that Fkbp9 isomerase activity may alter
the susceptibility of PrPC to conversion. Actr10 (also known as
Arp11) forms part of the pointed end complex of the dynactin
complex which is the dynein activator complex and is therefore
involved in the retrograde transport of cargos alongmicrotubules
(33). The participation of three of our candidates (Sorcs1, Stmn2
and Actr10) in trafficking identifies a common pathway central
to PrPSc accumulation in cells.
Overexpression of plasminogen (Plg) showed an increase in
PrPSc positive cells which is consistent with previous findings
that addition of plasminogen to N2a cell cultures increase
PrPSc levels following RML infection (20). These in vitro data
are in contrast to data from plasminogen-deficient mice that
showed no major effect of plasminogen on survival (22).
These data highlight the difficulty in assessing the contributions
of modifiers and reinforce the need for evaluating their function
in a variety of model systems.
In conclusion, we have generated stable knockdown and/or
overexpressing cell lines as part of an in vitro triage to test the
effect of modulating mRNA expression level on susceptibility
and prion propagation in the SCA for 14 candidate genes. No
consistent differences were seen for seven genes. In spite of
the limitations of this assay, it has proved to be a successful
triage with changes detected in at least two independent lines
for Zbtb38, Sorcs1, Stmn2, Hspa13, Fkbp9, Actr10 and Plg.
Based on these data, we will pursue mouse models for future
work particularly forFkbp9. Since all the major neurodegenera-
tive diseases involve accumulation of misfolded host-encoded
proteins and ‘prion-like’ seeded fibrillization may be relevant
to their pathogenesis and tissue spread (34–36), it is expected
that a proportion of these prion-modifier genes may be of
wider relevance in neurodegeneration.
MATERIALS AND METHODS
Cloning
19mer shRNA sequences were designed using http://www.therm
oscientificbio.com/design-center/, last accessed on 19 May 2014
or http://www.sirnawizard.com/, last accessed on 19 May 2014
design_advanced.php excluding sequences with C at position 1,
runs of two or more T at 3′ end or runs of four of the same base
and where possible avoiding runs of 3 A/U. shRNA oligonucleo-
tides were designed to be inserted into pSUPER.retro.puro
(Oligoengine) at the BglII and HindIII sites with a hairpin
(5′-TTCAAGAGA-3′) separating the reverse complement
19mer shRNA. Oligos are designed to form a stem loop structure
using the following sequences: top strand-5′GATCCCC target
sequence (sense) TTCAAGAGA target sequence (antisense)
TTTTTA 3′ and bottom strand-5′AGCTTAAAAA target
sequence (sense) TCTCTTGAA target sequence (antisense)
GGG 3′. Complementary single-stranded oligonucleotides were
annealed in annealing buffer [1 mM Tris–HCl (pH 7.5), 0.1 mM
EDTA, 5 mM NaCl] by heating to 958C for 2 min and cooled
slowly to room temperature. For overexpression, cDNA for the
gene of interest covering the open reading framewas PCR ampli-
fied from C57BL/6J mouse brain cDNA library (11) or plasmid
(Source Bioscience) and inserted into the multiple cloning site
of the retroviral vector pLNCX2 (Clontech).
Cell culture
N2aPK1/2 cells are highly susceptible to the Chandler/RML
strain of prions and were previously subcloned from the N2a
cell line (12). N2aPK1/2 cells were cultured in Opti-MEM,
10% FBS (Invitrogen), PenStrep (100 U/ml penicillin, 100 ug/ml
streptomycin; Invitrogen). Phoenix Ecotropic, w-NX Eco,
packaging cells (Insight Biotechnology) were cultured in com-
plete Dulbecco’s modified Eagle medium (Invitrogen) supple-
mented with 10% (v/v) Heat Inactivated FBS (Invitrogen) and
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1% (v/v) PenStrep (100 U/ml penicillin, 100 ug/ml streptomy-
cin; Invitrogen).
Generation of stable knockdown and overexpressing cells
Phoenix Ecotropic, w-NX Eco, packaging cell line (Insight Bio-
technology) was used to generate Moloney murine leukaemia
virus (MMLV) pseudotyped retroviral supernatants (37) that
were then used to infect N2aPK1/2 target cells. 1×106
Phoenix Eco cells were transfected with 7 mg pLNCX2 or pSu-
perRetro plasmid using Fugene HD (Promega) transfection
reagent. Viral supernatant was collected 48 h post-transfection
and added to 1 × 106 N2aPK1/2 cells in the presence of 8 mg/ml
polybrene (Millipore) for 6 h and placed under drug selection
[4 mg/ml puromycin or 500 ng/ml G418 (Sigma)] 48 h post-
infection. Transduced cells were cultured in drug selection
media for 2 weeks before gene expression analysis for stable
knockdown or overexpression thenmaintained in drug selection
media.
mRNA expression
A total of 10 000 cells were lysed using the TaqmanwGene Ex-
pression Cells to CT kit (Ambion, Life Technologies) and RNA
reverse transcribed according to the manufacturer’s protocol.
The resultant cDNA was then assayed by real-time quantitative
reverse transcription PCR using Fam-labelled TaqMan Gene
Expression assays (Life Technologies) in a duplex reaction
using Vic-labelled mouse GAPDH (Life Technologies) as an
endogenous control on the Applied Biosystems 7500 Fast
Real-Time PCR machine.
Scrapie cell assay (SCA)
All cell lines were infected with Chandler/RML prions and cul-
tured for 3 weeks, up to five 1:10 splits, before being assayed for
prion propagation as described previously (12). Briefly, 18 000
cells of each cell line were seeded in 6–12 wells in a 96-well
plate 24 h before exposure to RML homogenate (3 × 1025 to
1 × 1027 dilutions) and control brain homogenate (non-infected
CD-1 mouse) for 3 days. Cells were then split 1:10 every 3 or 4
days and assayed after four and five splits by ELISPOT assay.
For ELISPOT, 25 000 cells were plated and fixed (508C for
1 h), lysed and treated with protease K (12). Protease K resistant
PrP (PrPres) was then detected with ICSM18 monoclonal
anti-PrP antibody followed by alkaline phosphatase-linked
anti-IgG1 antiserum and visualized with alkaline phosphatase
conjugate substrate (Bio-Rad). PrPres positive cells were
counted using the Bioreader 5000-Eb (BioSys).
Cell growth
Tomeasure the growth of the stable cell lines, cell numbers were
counted at two time points 3 or 4 days apart and the cell doubling
time calculated using the equation: cell-doubling time (h) ¼
t/LOG(Nt/N0,2), where Nt ¼ cell number at endpoint, N0 ¼
starting cell number, t ¼ time (h).
Quantification of PrPC
Cells were lysed in 100 mM Tris (pH 7.4), 150 mM NaCl, 1 mM
EGTA, 1 mM EDTA, 1% Triton, 0.5% Deoxycholate, 1 mM
PMSF, with phosphatase inhibitor and protease inhibitor
tablets (Roche) to measure endogenous PrPC levels by ELISA
as previously described (38). Following a 1:10 dilution of the
lysis buffer, total protein concentration was measured using a
Coomassie (Bradford) protein assay kit (Bio-Rad) according to
the manufacturer’s instructions.
Statistical analysis
For each cell line, data from three independent SCAs (10–12
wells per assay) were normalized by the spot number obtained
for the relevant control cell line for statistical analysis using
either a t-test or non-parametric Mann–Whitney test.
Bonferonni-corrected significance at 1% is taken as P , 0.001
(for 14 genes). Statistical tests were carried out using GraphPad
InStat (GraphPad Software, Inc, California, USA) and SPSS
(IBM).
SUPPLEMENTARY MATERIAL
Supplementary Material is available at HMG online.
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